

Understanding Patient Priorities in Psoriasis Treatment: A Review of Key Decision-Making Drivers

PCR253



A. López Ferrer¹, I. Belinchón², M. Comellas Serra³, I. Esteban Martínez³, A. Romero Maté⁴, B. Pérez Suárez⁵, S. Santos Alarcón⁶ and P. De la Cueva⁷

1. Hospital Santa Creu i Sant Pau, Barcelona, Spain; 2. Dermatology Department, Dr. Balmis General University Hospital; Department of Clinical Medicine, Miguel Hernández University; ISABIAL, Alicante, Spain; 3. Outcomes'10 - A Productlife Group Company, Castellón de la plana, Spain; 4. Hospital Universitario de Fuenlabrada, Madrid, Spain; 5. Hospital Morales Meseguer, Murcia, Spain; 6. Hospital Universitario Doctor Peset, Valencia, Spain; 7. Hospital Universitario Infanta Leonor, Madrid, Spain

Introduction

Psoriasis is a chronic, immune-mediated skin disease with a significant impact on patients' physical and psychological well-being¹.

Treatment decision-making is complex, and understanding patient preferences is critical for optimizing outcomes and fostering shared decision-making².

Objectives

To identify and synthesize the key drivers influencing patient preferences for psoriasis treatments, with the aim of supporting shared decision-making in clinical practice.

Method

A structured literature review was conducted in PubMed to identify studies reporting on treatment decision-making and patient preferences in psoriasis.

Eligible publications included qualitative studies, discrete choice experiments (DCEs), systematic reviews of DCEs, and other relevant designs.

Data were extracted on study populations, treatment attributes assessed, and the relative importance of decision-making drivers.

Results

A total of 25 publications were included.

STUDY DESIGNS




Figure 1. Study Designs identified in the review

MAIN DECISION-MAKING DRIVERS




Figure 1. Study Designs identified in the review

Decision-making Driver	Key Attributes	Frequency of Studies
EFFICACY	Sustainability of treatment success	44%
	Duration of symptom relief	44%
CONVENIENCE	Treatment frequency	52%
	Route of administration	44%
SAFETY	Side effects	64%

Table 1. Main Key attributes

Conclusion

Patient preferences in psoriasis treatment are primarily driven by **efficacy** and **convenience**, with safety as a secondary factor.

Sustained symptom relief and reduced treatment burden are highly valued by patients.

While less frequently cited, **quality of life** and **treatment cost** remain relevant in shaping decisions.

Incorporating these drivers into **shared decision-making tools** is essential to align treatments with patients' values and daily realities.

REFERENCES

1. Bhosle, M.J., Kulkarni, A., Feldman, S.R. et al. Quality of life in patients with psoriasis. *Health Qual Life Outcomes* 4, 35 (2006). <https://doi.org/10.1186/1477-7525-4-35>
2. Armstrong AW, Puig L, Joshi A, Skup M, Williams D, Li J, Augustin M. Comparison of biologics and oral treatments for moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis. *JAMA Dermatology*. 2021;157(8):944–953.

CONTACT

Marta Comellas Serra



mcomellaserra@productlife-group.com



OUTCOMES¹⁰
A PRODUCTLIFEGROUP COMPANY

PLG
ProductLifeGroup